Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications

References

• Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005;8:140–174.
   PubMedGoogle Scholar
• Kaminski MS, Zelenetz AD, Press OW, et al Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918–3928.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Gordon LI, Cabanillas F, et al Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453–2463.
   PubMed Web of Science ®Google Scholar
• Dillman RO. Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies. Clin Exp Med 2006;6:1–12.
   PubMed Web of Science ®Google Scholar
• Gordon LI, Witzig TE, Wiseman GA, et al Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. Semin Oncol 2002;29(Suppl. 2):87–92.
   PubMed Web of Science ®Google Scholar
• Gordon LI. Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Semin Oncol 2003;30(Suppl. 17):23–28.
   PubMed Web of Science ®Google Scholar
• Ryan MT, Spicer KM, Frei-Lahr D, et al Health physics consequences of out-patient treatment of non-Hodgkin's lymphoma with 131I-radiolabeled anti-B1 antibody. Health Phys 2000;79(Suppl.):S52–55.
   PubMed Web of Science ®Google Scholar
• Quadri SM, Vriesendorp HM, Leichner PK, Williams JR. Evaluation of indium-111- and yttrium-90-labeled linker-immunoconjugates in nude mice and dogs. J Nucl Med 1993;34:938–945.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Fisher RI. Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma. Expert Rev Anticancer Ther 2004;4:18–26.
   PubMedGoogle Scholar
• Cheson BD. Radioimmunotherapy of non-Hodgkin lymphomas. Blood 2003;101:391–398.
   PubMed Web of Science ®Google Scholar
• Wagner HN Jr, Wiseman GA, Marcus CS, et al Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody. J Nucl Med 2002;43:267–272.
   PubMed Web of Science ®Google Scholar
• Witzig TE, White CA, Wiseman GA, et al Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3793–3803.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Flinn IW, Gordon LI, et al Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3262–3269.
   PubMed Web of Science ®Google Scholar
• Wiseman GA, Gordon LI, Multani PS, et al Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002;99:4336–4342.
   PubMed Web of Science ®Google Scholar
• Emmanouilides C, Witzig TE, Gordon LI, et al Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2006;47:629–636.
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Estes J, Zasadny KR, et al Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000;96:1259–1266.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Kaminski MS, Wahl RL, et al Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005;23:7565–7573.
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Tuck M, Estes J, et al 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441–449.
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Tuck M, Estes J, et al Tositumomab and iodine I-131 tositumomab for previously untreated, advanced-stage, follicular lymphoma: median 10 year follow-up results. Blood 2009;114(Suppl. 1): (Abstract 3759).
   Google Scholar
• Morschhauser F, Radford J, Van Hoof A, et al Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156–5164.
   PubMed Web of Science ®Google Scholar
• Press OW, Unger JM, Braziel RM, et al Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006;24:4143–4149.
   PubMed Web of Science ®Google Scholar
• Goff L, Summers K, Iqbal S, et al Quantitative PCR analysis for Bcl-2/IgH in a phase III study of yttrium-90 ibritumomab tiuxetan as consolidation of first remission in patients with follicular lymphoma. J Clin Oncol 2009;27:6094–6100.
   PubMed Web of Science ®Google Scholar
• Leonard JP, Coleman M, Kostakoglu L, et al Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005;23:5696–5704.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Illidge T, Huglo D, et al Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 2007;110:54–58.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Tani M, Fanti S, et al A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol 2008;19:769–773.
   PubMed Web of Science ®Google Scholar
• Available from: http://www.cancer.gov/clinicaltrials/ECOG-E3402
   Google Scholar
• Wang M, Oki Y, Pro B, et al Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27:5213–5218.
   PubMed Web of Science ®Google Scholar
• Weigert O, Von Schilling C, Rummel MJ. Efficacy and safety of a single-course of yttrium-90 ibritumomab tiuxetan for treatment of patients with relapsed or refractory mantle cell lymphoma after/not appropriate for autologous stem cell transplantation - final analysis of a phase II trial of the European MCL Network. Blood 2007;110(Suppl. 1): (Abstract 4501).
   Web of Science ®Google Scholar
• Jurczak W, Giza A, Krochmalczyk D, et al Survival benefit of post induction consolidation therapy in MCL (mantle cell lymphoma): a Polish Lymphoma Research Group (PLRG) retrospective multicenter analysis. J Clin Oncol 2009;27(Suppl.): Abstract 19510.
   Google Scholar
• Smith M, Chen L, Gordon LI, et al Phase II study of R-CHOP and 90Y-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma (E1499). J Clin Oncol 2006;24(Suppl.): Abstract 7503.
   Google Scholar
• Zelenetz AD, Noy A, Pandit-Taskar N, et al Sequential radioimmunotherapy with tositumomab/iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions. J Clin Oncol 2006;24(Suppl.): Abstract 7560.
   Google Scholar
• Press OW, Eary JF, Appelbaum FR, et al Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219–1224.
   PubMed Web of Science ®Google Scholar
• Devizzi L, Guidetti A, Tarella C, et al High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation. J Clin Oncol 2008;26:5175–5182.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Gooley TA, Maloney DG, et al High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 2003;102:2351–2357.
   PubMed Web of Science ®Google Scholar
• Press OW, Eary JF, Gooley T, et al A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000;96:2934–2942.
   PubMed Web of Science ®Google Scholar
• Nademanee A, Forman S, Molina A, et al A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005;106:2896–2902.
   PubMed Web of Science ®Google Scholar
• Winter JN, Inwards DJ, Spies S, et al Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2009;27:1653–1659.
   PubMed Web of Science ®Google Scholar
• Krishnan A, Nademanee A, Fung HC, et al Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2008;26:90–95.
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT00591630?term = zevalin+beam&rank = 6
   Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT00463463?term = zevalin+beam&rank = 4
   Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT00329030
   Google Scholar
• Fietz T, Uharek L, Gentilini C, et al Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan. Leuk Lymphoma 2006;47:59–63.
   PubMed Web of Science ®Google Scholar
• Shimoni A, Zwas ST, Oksman Y, et al Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma. Bone Marrow Transplant 2008;41:355–361.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Rajendran J, Pagel J, et al A phase II trial of 90Y-ibritumomab tiuxetan-based reduced intensity allogeneic peripheral blood stem cell (PBSC) transplantation for relapsed CD20+ B-cell non-Hodgkin's lymphoma (NHL). Blood 2006;108(Suppl. 1): (Abstract 316).
   Google Scholar
• Vose JM, Bierman PJ, Loberiza FR Jr, Bociek RG, Matso D, Armitage JO. Phase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation. Leuk Lymphoma 2007;48:683–690.
   PubMed Web of Science ®Google Scholar
• Jacobs SA, Vidnovic N, Joyce J, et al Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. Clin Cancer Res 2005;11:7146s–7150s.
   PubMed Web of Science ®Google Scholar
• Peyrade F, Triby C, Slama B, et al Radioimmunotherapy in relapsed follicular lymphoma previously treated by autologous bone marrow transplant: a report of eight new cases and literature review. Leuk Lymphoma 2008;49:1762–1768.
   PubMed Web of Science ®Google Scholar
• Witzig TE, White CA, Gordon LI, et al Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 2003;21:1263–1270.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Emmanouilides C, Darif M, et al Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol 2007;25:4285–4292.
   PubMed Web of Science ®Google Scholar
• Gordon LI, Witzig T, Molina A, et al Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 2004;5:98–101.
   PubMedGoogle Scholar
• Kaminski MS, Radford JA, Gregory SA, et al Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. J Clin Oncol 2005;23:7985–7993.
   PubMed Web of Science ®Google Scholar
• Jacobs SA, Swerdlow SH, Kant J, et al Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res 2008;14:7088–7094.
   PubMed Web of Science ®Google Scholar
• Lopci, E, Santi, I, Derenzini, E, et al (2008) FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study Ann Oncol 2010 Feb 10. [Epub ahead of print].
   Google Scholar
• Cazaentre T, Morschhauser F, Vermandel M, et al Pre-therapy (18)F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2010;37:494–504.
   PubMed Web of Science ®Google Scholar
• Evens AM, Spies WG, Helenowski IB, et al The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial. Clin Cancer Res 2009;15:6462–6471.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Wiseman GA, Weiner G, et al A phase I trial of CpG-7909, rituximab immunotherapy, and Y90 Zevalin radioimmunotherapy for patients (pts) with previously treated CD20+ non-Hodgkin lymphoma. Blood 2007;110(Suppl. 1): (Abstract 124).
   Google Scholar
• Bortezomib, rituximab, and yttrium Y 90 ibritumomab tiuxetan in treating patients with relapsed or refractory low-grade, follicular, or mantle cell non-Hodgkin's lymphoma. Available from: http://clinicaltrials.gov/ct2/show/NCT00334438.
   Google Scholar
• O'Connor OA, Portlock C, Moskowitz C, et al Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clin Cancer Res 2010;16:719–726.
   PubMed Web of Science ®Google Scholar
• Pervan M, Calimlim J, Matso D, et al Active combination therapy of bortezomib (Velcade) and ibritumomab tiuxetan (Zevalin) in an in vivo diffuse large B-cell lymphoma model. Blood 2005;106(Suppl. 1): (Abstract 2406).
   Google Scholar
• Illidge TM, Bayne M, Brown NS, et al Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood 2009;113:1412–1421.
   PubMed Web of Science ®Google Scholar
• Bodet-Milin C, Kraeber-Bodere F, Dupas B, et al Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography. Haematologica 2008;93:390–397.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Press OW, Wilbur SM, Maloney DG, Pagel JM. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood 2008;112:830–835.
   PubMedGoogle Scholar
• Pagel JM, Orgun N, Hamlin DK, et al A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations. Blood 2009;113:4903–4913.
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Karacay H, Johnson CR, et al Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma. J Nucl Med 2009;50:444–453.
   PubMed Web of Science ®Google Scholar
• Dewaraja YK, Wilderman SJ, Koral KF, et al Use of integrated SPECT/CT imaging for tumor dosimetry in I-131 radioimmunotherapy: a pilot patient study. Cancer Biother Radiopharm 2009;24:417–426.
   PubMed Web of Science ®Google Scholar
• Leonard JP, Zelenetz A, Vose JM, et al Iodine 131 tositumomab for patients with low-grade or transformed low grade NHL: complete response data. Blood 2000;96(Suppl. 1): (Abstract 728).
   Google Scholar
• Vose JM, Wahl RL, Saleh M, et al Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000;18:1316–1323.
   PubMed Web of Science ®Google Scholar
• Gockerman J, Gregory S, Harwood S, et al Interim efficacy results of Bexxar in a large multicenter expanded access study. J Clin Oncol 2001;20(Suppl.): (Abstract 1137).
   Google Scholar
• Horning SJ, Younes A, Jain V, et al Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005;23:712–719.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Tani M, Fanti S, et al A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. Cancer 2008;112:856–862.
   PubMed Web of Science ®Google Scholar
• Hamlin, P, Moskoqitz, C, Wegner, B, et al (2008) Sequential RCHOP and yttrium-90 ibritumomab tiuxetan (RIT) is a highly effective regimen for high risk elderly patients with untreated DLBCL. Paper presented at 10th International Conference on Malignant Lymphoma, 4–7 June 2008, Lugano, Switzerland; Abstract 054.
   Google Scholar
• Liu SY, Eary JF, Petersdorf SH, et al Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998;16:3270–3278.
   PubMed Web of Science ®Google Scholar
• Vose JM, Bierman PJ, Enke C, et al Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 2005;23:461–467.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Rajendran JG, Gooley TA, et al High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol 2007;25:1396–1402.
   PubMed Web of Science ®Google Scholar
• Kolstad A, Laurell A, Andersen NS, et al 90Y-ibritumumab tiuxetan (Zevalin®)-BEAM/C with autologous stem cell support as frontline therapy for advanced mantle cell lymphoma. – preliminary results from the Third Nordic MCL Phase II Study (MCL3). Blood 2009;114(Suppl. 1): (Abstract 932).
   PubMed Web of Science ®Google Scholar